Rhythm’s ColoSTAT® has the potential to be a ground-breaking solution to early cancer screening. It will be the first blood-based detection method for colorectal cancer in Australia which is a significant departure from traditional faecal testing, and it will provide a scientifically rigorous approach to early cancer detection. 

ColoSTAT® has huge transformative impact potential as it will simplify the cancer screening process, reduce unnecessary invasive procedures, provide a more accessible screening method, and potentially catch cancer at earlier, more treatable stages. 

The clinical and economic benefits include: 

• Reduced false positives in current screening methods 

• Triage of patients more effectively for further investigation 

• Potentially decrease healthcare system burden 

• Improve patient outcomes through early detection 

World-leading personalised predictive test portfolio  

geneType™ is a world-leading portfolio of personalised predictive tests that combines genomic and clinical information to forecast an individual’s risk of developing chronic diseases. This innovative approach empowers both patients and healthcare providers to take proactive steps toward better health outcomes, ushering in a new era of personalised medicine. 

The geneType™ portfolio includes our patented Multi Risk Test (MRT) that assesses multiple conditions simultaneously, and our Hereditary Breast and Ovarian Cancer (HBOC) test, a comprehensive screening tool currently available in the US market. 

Since its 2021 launch in the US and Australia, the Multi Risk Test has delivered remarkable results, with 79.5% of tests providing novel health insights previously unknown to patients. Our clinical performance has been well-established through peer-reviewed publications, demonstrating significant advances in risk detection. 

With 25 granted patents and 9 pending, geneType™ represents the cutting edge of predictive diagnostics. We’re rapidly gaining commercial traction with medical providers and payers, with several key partnerships nearing finalisation.